Neurology Alert – September 1, 2019

September 1, 2019

• Antisense Oligonucleotide Treatment of Huntington’s Disease: A Novel Potential Treatment

  In this Phase I/IIa clinical trial, investigators administered antisense huntingtin oligonucleotides intrathecally to patients with early Huntington’s disease (HD), and demonstrated safety, tolerability, and dose-dependent reduction in CSF mutant huntingtin. This approach now is being tested for clinical efficacy in HD in a Phase III clinical trial.

  Read more

• Calcitonin Gene-Related Peptide Targeting Therapies for Migraine

  Two randomized clinical trials showed that calcitonin gene-related peptide targeting therapies are effective and safe for primary headache disorders.

  Read more

• Targeting Fyn Kinase in Alzheimer’s Disease: Another Failed Clinical Trial

  In this multicenter Phase IIa clinical trial in mild Alzheimer’s disease dementia, the tyrosine kinase Fyn inhibitor AZD0540 had no significant effects after 52 weeks of treatment.

  Read more

• Risk of Neuropathy With Fluoroquinolones

  As a class, fluoroquinolones are some of the most commonly used antibiotics worldwide. Their use carries a significant risk of neurotoxicty, for both the peripheral and central nervous system.

  Read more

• Racial and Ethnic Disparities in Thrombectomy in the United States

  Disparities of treatment for stroke across various ethnic and racial groups need to be examined carefully to ensure uniform application of this treatment.

  Read more

• After Ischemic Stroke Related to Atrial Fibrillation, Direct Oral Anticoagulants Are Superior to Vitamin K Antagonists

  The authors of this trial investigated the benefits and risks of early anticoagulation following acute ischemic stroke, and compared the effects of direct oral anticoagulants vs. vitamin K antagonists. Overall, treatment with direct oral anticoagulants resulted in a reduced risk of poor clinical outcomes, primarily due to reduced risk of intracerebral hemorrhage.

  Read more

• Faster Time to Endovascular Reperfusion Therapy Results in Better Outcomes

  Endovascular reperfusion therapy has been demonstrated to be of benefit for the treatment of large vessel occlusion in patients with acute ischemic stroke.

  Read more